Elevance Health (ELV) slides as investors refocus on CMS compliance overhang ahead of key late-June deadline

Elevance Health (ELV) is down 4.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to renewed regulatory-risk sensitivity around Elevance’s Medicare Advantage risk-adjustment data compliance, with a firm deadline later this month that could still lead to sanctions if remediation milestones are missed. The stock also went ex-dividend today, which can mechanically pressure shares, though that typically explains only a small portion of a multi-percent drop.

Details:

Sources:

CMS, Elevance Health (Investor Relations), MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ELV Insider Trading Activity

$ELV insiders have traded $ELV stock on the open market 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $ELV stock by insiders over the last 6 months:

• CHARLES MORGAN JR KENDRICK (EVP & President, Commercial) sold 3,196 shares for an estimated $910,604
• STEVEN H COLLIS purchased 3,000 shares for an estimated $869,519
• RONALD W PENCZEK (CAO & Controller) sold 1,531 shares for an estimated $617,192
• AMY W SCHULMAN sold 26 shares for an estimated $7,475

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$ELV Hedge Fund Activity

We have seen 618 institutional investors add shares of $ELV stock to their portfolio, and 943 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• PRICE T ROWE ASSOCIATES INC /MD/ removed 2,699,600 shares (-36.3%) from their portfolio in Q1 2026, for an estimated $785,867,058
• AMUNDI added 1,597,497 shares (+145.7%) to their portfolio in Q1 2026, for an estimated $465,039,364
• INVESCO LTD. added 1,306,390 shares (+50.3%) to their portfolio in Q4 2025, for an estimated $457,955,014
• ORBIS ALLAN GRAY LTD removed 1,061,755 shares (-85.3%) from their portfolio in Q1 2026, for an estimated $309,082,189
• GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC removed 592,814 shares (-23.4%) from their portfolio in Q1 2026, for an estimated $172,571,119
• SG AMERICAS SECURITIES, LLC added 561,300 shares (+238.6%) to their portfolio in Q1 2026, for an estimated $163,397,236
• CAPITAL INTERNATIONAL INVESTORS removed 536,582 shares (-33.8%) from their portfolio in Q1 2026, for an estimated $156,201,703

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ELV Government Contracts

We have seen $288,996,419 of award payments to $ELV over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

• PART A/PART B MEDICARE ADMINISTRATIVE CONTRACTOR (MAC) JURISDICTION K (JK): $134,570,476
• J6 A/B MAC SERVICES: $80,538,334
• NEXT GENERATION DESKTOP IGF::OT::IGF: $52,070,094
• SPARC WILL BE THE MAJOR CONTRACT VEHICLE FOR CMS IT SYSTEMS AND SUPPORT HHS OPDIVS CAN ALSO MAKE USE OF SPA...: $11,890,083
• THE CONTRACTOR SHALL PROVIDE SUPPLIES AND/OR SERVICES TO PROVIDE A SINGLE FRONT-END SOLUTION FOR THE SUBMIS...: $4,213,107

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$ELV Congressional Stock Trading

Members of Congress have traded $ELV stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $ELV stock by members of Congress over the last 6 months:

• SENATOR MARKWAYNE MULLIN purchased up to $50,000 on 12/29.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$ELV Analyst Ratings

Wall Street analysts have issued reports on $ELV in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

• Barclays issued a "Overweight" rating on 01/30/2026
• Wells Fargo issued a "Overweight" rating on 01/30/2026

To track analyst ratings and price targets for $ELV, check out Quiver Quantitative's $ELV forecast page.

$ELV Price Targets

Multiple analysts have issued price targets for $ELV recently. We have seen 14 analysts offer price targets for $ELV in the last 6 months, with a median target of $437.5.

Here are some recent targets:

• Lisa Gill from JP Morgan set a target price of $476.0 on 06/08/2026
• Ann Hynes from Mizuho set a target price of $465.0 on 06/08/2026
• Erin Wright from Morgan Stanley set a target price of $404.0 on 06/04/2026
• Kevin Fischbeck from B of A Securities set a target price of $460.0 on 06/04/2026
• David Macdonald from Truist Securities set a target price of $450.0 on 06/01/2026
• Andrew Mok from Barclays set a target price of $480.0 on 05/26/2026
• A.J. Rice from UBS set a target price of $460.0 on 05/22/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.